Clinical Trials Directory
We are doing this study to find out if an experimental drug called brepocitinib (the study drug) is a safe and effective option for people with cutaneous sarcoidosis.
We are doing this study to find out if an experimental drug called BGB-43395 (the study drug) is a safe and effective option for people with for breast cancer and other advanced solid tumors. We want to know how the study drug works on its own and in combination with other cancer drugs.
We are doing this study to find the most safe and effective long-term dose of an experimental drug called zanubrutinib (the study drug) when it is given alone or in combination with other cancer drugs. We want to know how well this study drug works in people with B-cell cancers who are currently participating or previously participated in a BeiGene-sponsored study.
We are doing this study to monitor the health of the cornea in participants with neovascular age-related macular degeneration (nAMD), also know as wet AMD, who receive an eye implant that continuously delivers the drug ranibizumab into the back of the eye.
We are doing this study to collect data, liquid biopsies (blood and urine), and cancer specimens from women with primary epithelial ovarian, peritoneal, or tubal cancer. We are using this information and these samples to create a biobank that might identify future therapeutic targets and help develop new therapies for these types of cancer.
Collection of samples will allow for increased and more focused research on skin conditions and perhaps eventually lead to the development of improved treatment outcomes.
We are doing this study to learn more about how repeated head impacts and concussions from playing sports can impact the health of Black men after middle age (age 50 and above). We want to find out how these injuries might affect things like lifestyle, mood, brain structure, socioeconomic status, and blood markers of brain disease. We hope this study can help reduce disparities in outcomes and improve the detection and diagnosis of brain health.
We are doing this study to find out if an experimental drug called ruxolitinib is a safe and effection option for preventing graft-versus-host disease when it is given in combination with the drugs tacrolimus and methotrexate before and after a peripheral blood stem cell transplant. We want to know if this study drug combination works better than the standard post-transplant treatment of cyclophosphamide, tacrolimus, and mycophenolate mofetil.